Pearce IP BioBlast: w/e 24 Apr 2020
Significant biosimilar activities this week include:
On 21 April 2020, the Centre for Biosimilars reported that Xbrane Pharma was continuing clinical trials of its ranibizumab candidate and remained on-track for target dates for regulatory filings despite CoVid-19.
On 23 April 2020, the Centre for Biosimilars reported that COVID-19 could speed up biosimilar uptake in the US. Factors which may influence this include widespread unemployment (lack of health insurance to pay for costly originator products), faster adoption of bills that support biosimilar uptake, and potential health care payment model changes.
On 23 April 2020, a presentation at the American Academy of Managed Care Pharmacy eLearning Days discussed future biosimilar launches in the US. A particular emphasis was placed on the number of adalimumab biosimilars waiting to come to market, with competition in this space expected to heat up in 2023. Possible biosimilar launches for 2020 which were discussed include pegfilgrastim, bevacizumab and rituximab.
On 24 April 2020, Johnson & Johnson announced it had filed two supplemental marketing applications for Simponi Aria (golimumab) with the FDA. J&J hasapplied for the additional indications of polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis in patients at least two years old.